Skipping chemotherapy for older women with hormone-positive breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether women aged 65 and older with a certain type of early breast cancer can safely skip chemotherapy and instead receive a pill that helps stop cancer cells from growing. The goal is to reduce treatment side effects while keeping the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 65 or older.
- You had surgery for early-stage breast cancer that is hormone receptor-positive and HER2-negative.
- Your cancer has spread to at least one lymph node, and you have other high-risk features.
- You have not had any chemotherapy, radiation, or hormone therapy before surgery.
- You are willing to take a CDK4/6 inhibitor pill for at least two years after surgery.
- You are generally healthy enough for daily activities and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a pill (a CDK4/6 inhibitor) used alone, without chemotherapy, is effective for older women with early-stage hormone-positive breast cancer. The goal is to reduce the risk of cancer returning while avoiding the side effects of chemo.
This study tests whether some patients with early-stage, hormone-positive breast cancer can safely skip chemotherapy and just use hormone therapy plus a CDK4/6 inhibitor pill after surgery. If you qualify, you may avoid chemo side effects while still reducing the chance of the cancer coming back.
This trial tests whether adding a targeted pill (dalpiciclib) to standard hormone therapy can safely replace chemotherapy for women with small, hormone-positive, high-risk breast cancers.
This trial tests whether women with certain aggressive breast cancers (HER2-positive without hormone receptors, or triple-negative) can safely skip breast surgery if chemotherapy makes their tumor completely disappear. The goal is to avoid surgery and its side effects when it may no longer be needed.
This trial tests whether adding a targeted therapy (a CDK4/6 inhibitor) to standard hormone therapy can let some people safely skip chemotherapy. It is for early-stage, hormone-positive breast cancer that is also HER2-positive, and aims to reduce side effects while keeping the cancer from coming back.
This trial tests whether older women with very low-risk, hormone-positive breast cancer can safely skip endocrine therapy (hormone-blocking pills) and radiation after lumpectomy. It aims to maintain quality of life while keeping cancer from coming back.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.